Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT03945188 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT03945188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03945188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2019
Completion date
February 16, 2022
Enrollment
433 (actual)
Sites
315

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis